Your browser doesn't support javascript.
loading
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
Räuber, Saskia; Korsen, Melanie; Huntemann, Niklas; Rolfes, Leoni; Müntefering, Thomas; Dobelmann, Vera; Hermann, Alexander M; Kölsche, Tristan; von Wnuck Lipinski, Karin; Schroeter, Christina B; Nelke, Christopher; Regner-Nelke, Liesa; Ingwersen, Jens; Pawlitzki, Marc; Teegen, Bianca; Barnett, Michael Harry; Hartung, Hans-Peter; Aktas, Orhan; Albrecht, Philipp; Levkau, Bodo; Melzer, Nico; Ruck, Tobias; Meuth, Sven G; Kremer, David.
Afiliación
  • Räuber S; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Korsen M; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Huntemann N; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Rolfes L; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Müntefering T; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Dobelmann V; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Hermann AM; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Kölsche T; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • von Wnuck Lipinski K; Institute of Molecular Medicine III, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Schroeter CB; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Nelke C; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Regner-Nelke L; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Ingwersen J; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Pawlitzki M; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Teegen B; Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.
  • Barnett MH; Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
  • Hartung HP; Sydney Neuroimaging Analysis Centre, The University of Sydney, Camperdown, New South Wales, Australia.
  • Aktas O; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Albrecht P; Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
  • Levkau B; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Melzer N; Department of Neurology, Palacky University, Olomouc, Czech Republic.
  • Ruck T; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Meuth SG; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Kremer D; Institute of Molecular Medicine III, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
J Neurol Neurosurg Psychiatry ; 93(9): 978-985, 2022 09.
Article en En | MEDLINE | ID: mdl-35193952
BACKGROUND: Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients with multiple sclerosis (MS) receiving immunomodulatory therapies. METHODS: We performed a retrospective study including 59 ocrelizumab (OCR)-treated patients with MS who received SARS-CoV-2 vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters and peripheral immune cell profiles were measured prior to the first (baseline) and at a median of 4 weeks after the second vaccine dose (follow-up). Moreover, the SARS-CoV-2-specific T cell response and peripheral B cell subsets were analysed at follow-up. Finally, vaccination-related adverse events were assessed. RESULTS: After vaccination, we found anti-SARS-CoV-2(S) antibodies in 27.1% and a SARS-CoV-2-specific T cell response in 92.7% of MS cases. T cell-mediated interferon (IFN)-γ release was more pronounced in patients without anti-SARS-CoV-2(S) antibodies. Antibody titres positively correlated with peripheral B cell counts, time since last infusion and total IgM levels. They negatively correlated with the number of previous infusion cycles. Peripheral plasma cells were increased in antibody-positive patients. A positive correlation between T cell response and peripheral lymphocyte counts was observed. Moreover, IFN-γ release was negatively correlated with the time since the last infusion. CONCLUSION: In OCR-treated patients with MS, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. However, it is still unclear whether T or B cell-mediated immunity is required for effective clinical protection. Nonetheless, given the long-lasting clinical effects of OCR, monitoring of peripheral B cell counts could facilitate individualised treatment regimens and might be used to identify the optimal time to vaccinate.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 / Esclerosis Múltiple Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 / Esclerosis Múltiple Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido